Literature DB >> 15318176

Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters.

Catia Morelli1, Cecilia Garofalo, Diego Sisci, Sonia del Rincon, Sandra Cascio, Xiao Tu, Andrea Vecchione, Edward R Sauter, Wilson H Miller, Eva Surmacz.   

Abstract

Insulin receptor substrate 1 (IRS-1) is a major signaling molecule activated by the insulin and insulin-like growth factor I receptors. Recent data obtained in different cell models suggested that in addition to its conventional role as a cytoplasmic signal transducer, IRS-1 has a function in the nuclear compartment. However, the role of nuclear IRS-1 in breast cancer has never been addressed. Here we report that in estrogen receptor alpha (ERalpha)-positive MCF-7 cells, (1) a fraction of IRS-1 was translocated to the nucleus upon 17-beta-estradiol (E2) treatment; (2) E2-dependent nuclear translocation of IRS-1 was blocked with the antiestrogen ICI 182,780; (3) nuclear IRS-1 colocalized and co-precipitated with ERalpha; (4) the IRS-1:ERalpha complex was recruited to the E2-sensitive pS2 gene promoter. Notably, IRS-1 interaction with the pS2 promoter did not occur in ERalpha-negative MDA-MB-231 cells, but was observed in MDA-MB-231 cells retransfected with ERalpha. Transcription reporter assays with E2-sensitive promoters suggested that the presence of IRS-1 inhibits ERalpha activity at estrogen-responsive element-containing DNA. In summary, our data suggested that nuclear IRS-1 interacts with ERalpha and that this interaction might influence ERalpha transcriptional activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15318176     DOI: 10.1038/sj.onc.1208014

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Authors:  C Giordano; S Catalano; S Panza; D Vizza; I Barone; D Bonofiglio; L Gelsomino; P Rizza; S A W Fuqua; S Andò
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

2.  In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancer.

Authors:  Stefania Catalano; Loredana Mauro; Daniela Bonofiglio; Michele Pellegrino; Hongyan Qi; Pietro Rizza; Donatella Vizza; Gianluca Bossi; Sebastiano Andò
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

3.  Expression of nuclear insulin receptor substrate 1 in breast cancer.

Authors:  Diego Sisci; Catia Morelli; Cecilia Garofalo; Francesco Romeo; Lucio Morabito; Filomena Casaburi; Emilia Middea; Sandra Cascio; Elvira Brunelli; Sebastiano Andò; Eva Surmacz
Journal:  J Clin Pathol       Date:  2006-08-01       Impact factor: 3.411

4.  Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter.

Authors:  F De Amicis; S Zupo; M L Panno; R Malivindi; F Giordano; I Barone; L Mauro; S A W Fuqua; S Andò
Journal:  Mol Endocrinol       Date:  2009-01-15

5.  Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.

Authors:  Yasir H Ibrahim; Sara A Byron; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

6.  Insulin receptor substrate-2 regulates aerobic glycolysis in mouse mammary tumor cells via glucose transporter 1.

Authors:  Shannon L Pankratz; Ernest Y Tan; Yumiko Fine; Arthur M Mercurio; Leslie M Shaw
Journal:  J Biol Chem       Date:  2008-12-04       Impact factor: 5.157

7.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

8.  Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.

Authors:  Catia Morelli; Marilena Lanzino; Cecilia Garofalo; Pamela Maris; Elvira Brunelli; Ivan Casaburi; Stefania Catalano; Rosalinda Bruno; Diego Sisci; Sebastiano Andò
Journal:  Mol Cell Biol       Date:  2009-11-23       Impact factor: 4.272

9.  Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Authors:  Ilenia Migliaccio; Meng-Fen Wu; Carolina Gutierrez; Luca Malorni; Syed K Mohsin; D Craig Allred; Susan G Hilsenbeck; C Kent Osborne; Heidi Weiss; Adrian V Lee
Journal:  Breast Cancer Res Treat       Date:  2009-11-19       Impact factor: 4.872

10.  Expression and function of the insulin receptor substrate proteins in cancer.

Authors:  Katerina Mardilovich; Shannon L Pankratz; Leslie M Shaw
Journal:  Cell Commun Signal       Date:  2009-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.